The unintentional theme of today’s issue is the struggle for control over how we implement AI in the U.S. On one side, where ...

The U.S. Digital Therapeutics Market encompasses software-driven solutions designed to prevent, manage, and treat medical conditions and diseases through evidence-based, clinically validated digital ...

Tech companies are focusing on AI products over research, say industry experts, who are sounding the alarm about safety.

Read about the move to scale use of AI across all FDA centers by the end of June and learn more about future plans to expand ...

There could be an upside to incorporating AI for the FDA. Using AI to assist in final drug reviews would "represent a chance ...

AI-powered tools are enhancing precision, efficiency, and decision-making in biopharmaceutical development. Recently, Jared ...

The Food and Drug Administration is rolling out an aggressive plan to make generative AI a linchpin in its decision-making, ...

Experts have cautioned against adopting the technology too quickly for clinical purposes. The first meeting of FDA’s Digital ...

The US Food and Drug Administration (FDA) has set an "aggressive" timeline to implement generative artificial intelligence ...

Donald Trump has promised to create a pro-AI environment, but even tech companies are frustrated by federal cuts that hamper regulatory processes. Paul Webster reports.

The Food and Drug Administration on Thursday announced an aggressive agency-wide Artificial intelligence adoption timeline ...

The Food and Drug Administration is going all in on artificial intelligence. | The Food and Drug Administration is going all ...